-

Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes.

As previously announced, in light of Hologic’s pending acquisition by Blackstone and TPG, the Company will not be hosting a quarterly conference call or providing financial guidance.

About Hologic

Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com.

SOURCE: Hologic, Inc.

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Industry:

Hologic, Inc.

NASDAQ:HOLX
Release Summary
Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026
Release Versions
English
$Cashtags
$HOLX
Hashtags
#earnings
#holx

Contacts

Paula Izidoro
Manager, Investor Relations and Social Media
(858) 410-8904
paula.izidoro@hologic.com

Social Media Profiles
Hologic Facebook
Hologic Instagram
Hologic LinkedIN
Hologic Twitter
Hologic YouTube
More News From Hologic, Inc.

Hologic’s New Sustainability Report Marks 40 Years of Impact

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc., a global leader in women’s health, today released its 2025 Sustainability Report. The new report coincides with Hologic’s 40th anniversary and underscores how the company’s longstanding purpose — to enable healthier lives for women everywhere, every day — continues to drive progress for patients, communities and the planet. “We have always firmly believed that our success as a company is fundamentally tied to our ability and commitment to help...

Hologic Secures Significant Patent Victory Against Siemens Over Breast Cancer Detection Technology

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. today announced a significant and far-reaching victory in the Unified Patent Court (UPC) in Germany, which ruled that Siemens* infringed upon a critical Hologic mammography technology patent in Siemens’ latest mammography system. The court imposed a sweeping injunction, immediately prohibiting Siemens from making, offering, placing on the market, using or importing or storing for those purposes its MAMMOMAT B.brilliant systems across Germany, F...

Hologic to Present New Data at ASCO 2026 Demonstrating the Clinical Impact of the Breast Cancer Index® Test on Extended Endocrine Therapy Decisions

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Hologic, Inc. and its subsidiary, Biotheranostics, Inc., today announced new data demonstrating how the Breast Cancer Index® (BCI™) Test results influence extended endocrine therapy decisions for patients with early-stage, hormone receptor-positive (HR+) breast cancer. According to the latest analysis, physician recommendations for extended endocrine therapy increased by more than 30% among patients identified by the BCI Test as likely to benefit, while reco...
Back to Newsroom